The incurable wound revisited: progress in human rabies prevention?

被引:32
作者
Hanlon, CA [1 ]
Niezgoda, M [1 ]
Morrill, PA [1 ]
Rupprecht, CE [1 ]
机构
[1] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Rabies Sect MS G33, Atlanta, GA 30333 USA
关键词
rabies; immune globulin; lyssaviruses;
D O I
10.1016/S0264-410X(00)00516-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rabies is the most important viral zoonosis from a global perspective. Modern human postexposure prophylaxis consists of potent vaccines and local infiltration of rabies immune globulins (RIGs), but the latter biologicals are not widely available or affordable. Monoclonal antibodies (Mabs) offer several theoretical advantages over RIGs. To this end, several human and equine RIGS. alone or in combination with vaccine, were investigated for postexposure efficacy in a Syrian hamster model, compared with a single neutralizing murine Mab. Preliminary results suggest that: (1) animal models continue to provide utility as human surrogates in the demonstration of product efficacy against rabies; (2) RIG preparations differ substantially in experimental effectiveness and clearance; and (3) relevant alternatives, such as Mabs, should be pursued for future improvements to human rabies prevention. Published by Elsevier Science Ltd.
引用
收藏
页码:2273 / 2279
页数:7
相关论文
共 48 条
[21]   USE OF HYPERIMMUNE ANTIRABIES SERUM CONCENTRATES IN EXPERIMENTAL RABIES [J].
KOPROWSKI, H ;
VANDERSCHEER, J ;
BLACK, J .
AMERICAN JOURNAL OF MEDICINE, 1950, 8 (04) :412-420
[22]   HUMAN MONOCLONAL-ANTIBODIES SPECIFIC FOR THE RABIES VIRUS GLYCOPROTEIN AND N PROTEIN [J].
LAFON, M ;
EDELMAN, L ;
BOUVET, JP ;
LAFAGE, M ;
MONTCHATRE, E .
JOURNAL OF GENERAL VIROLOGY, 1990, 71 :1689-1696
[23]   Development of orphan vaccines: An industry perspective [J].
Lang, J ;
Wood, SC .
EMERGING INFECTIOUS DISEASES, 1999, 5 (06) :749-756
[24]   Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine [J].
Lang, J ;
Attanath, P ;
Quiambao, B ;
Singhasivanon, V ;
Chanthavanich, P ;
Montalban, C ;
Lutsch, C ;
Pepin-Covatta, S ;
Le Mener, V ;
Miranda, M ;
Sabchareon, A .
ACTA TROPICA, 1998, 70 (03) :317-333
[25]  
LIN FT, 1988, REV INFECT DIS, V10, pS766
[26]  
Meslin F X, 1994, Curr Top Microbiol Immunol, V187, P1
[27]  
METZLER MI, 1998, PHARMACOECONOMICS, V14, P365
[28]  
METZLER MI, 1998, PHARMACOECONOMICS, V14, P481
[29]  
MILLER RG, 1981, SURVIVAL ANAL, P238
[30]   Mass human exposure to rabies in New Hampshire: Exposures, treatment, and cost [J].
Noah, DL ;
Smith, MG ;
Gotthardt, JC ;
Krebs, JW ;
Green, D ;
Childs, JE .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (08) :1149-1151